Cargando…

Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response

BACKGROUND: N6-methyladenosine (m6A) modification plays an essential role in diverse key biological processes and may take part in the development and progression of hepatocellular carcinoma (HCC). Here, we systematically analyzed the expression profiles and prognostic values of 13 widely reported m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Hongye, Ning, Gang, Wang, Yensheng, Lv, Weibiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213471/ https://www.ncbi.nlm.nih.gov/pubmed/34221187 http://dx.doi.org/10.1155/2021/5576683

Ejemplares similares

Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration
por: Ding, Lijuan, et al.
Publicado: (2023)

Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma
por: Cai, Jialiang, et al.
Publicado: (2022)

Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma
por: Yuan, Wei, et al.
Publicado: (2021)

Innovative Systems to Deliver Allergen Powder for Epicutaneous Immunotherapy
por: Wang, Yensheng, et al.
Publicado: (2021)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
por: Fu, Xing, et al.
Publicado: (2022)

A circadian clock gene-related signature for predicting prognosis and its association with sorafenib response in hepatocellular carcinoma
por: Liang, Qing, et al.
Publicado: (2023)

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma
por: Kang, Junwei, et al.
Publicado: (2022)

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
por: Chen, San-Chi, et al.
Publicado: (2022)

14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients
por: Jiang, Hong-ye, et al.
Publicado: (2020)

Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy
por: Yu, Lihua, et al.
Publicado: (2022)

Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma
por: Shi, Yanlong, et al.
Publicado: (2022)

HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
por: Chen, Guoming, et al.
Publicado: (2023)

A novel hepatocellular carcinoma-specific mTORC1-related signature for anticipating prognosis and immunotherapy
por: Chen, Erbao, et al.
Publicado: (2023)

Autophagy-related genes prognosis signature as potential predictive markers for immunotherapy in hepatocellular carcinoma
por: Mao, Deli, et al.
Publicado: (2020)

Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma
por: Liu, Furong, et al.
Publicado: (2020)

A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
por: Yang, Yongyu, et al.
Publicado: (2022)

Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma
por: Ye, Jianzhong, et al.
Publicado: (2023)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
por: Zeng, Weibiao, et al.
Publicado: (2023)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol–sorafenib hybrids
por: Awasthi, Bhuwan Prasad, et al.
Publicado: (2021)

Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review
por: Long, Xin, et al.
Publicado: (2022)

Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma
por: Feng, Qian, et al.
Publicado: (2023)

Guanylate‐binding proteins signature predicts favorable prognosis, immune‐hot microenvironment, and immunotherapy response in hepatocellular carcinoma
por: Ning, Yumei, et al.
Publicado: (2023)

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
por: Zheng, Yi, et al.
Publicado: (2019)

Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
por: Xu, Liqin, et al.
Publicado: (2022)

Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma
por: Li, Ning, et al.
Publicado: (2022)

Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy
por: Liu, Can, et al.
Publicado: (2018)

Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma
por: Zhang, Ze, et al.
Publicado: (2022)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2015)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

A Starvation-Based 9-mRNA Signature Correlates With Prognosis in Patients With Hepatocellular Carcinoma
por: Lei, Dengliang, et al.
Publicado: (2021)

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
por: Chen, Jiang, et al.
Publicado: (2016)

Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Zhang, Bo, et al.
Publicado: (2022)

A novel pyroptosis-regulated gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma
por: Zhang, Baozhu, et al.
Publicado: (2022)

An inflammation‐associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma
por: Ruan, Wan‐Yuan, et al.
Publicado: (2023)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma
por: Li, Lili, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gp56mjeiq7bjof9m36njcsii3v